Published in Circ Res on September 06, 2007
Three-dimensional structure of vertebrate cardiac muscle myosin filaments. Proc Natl Acad Sci U S A (2008) 2.39
In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res (2011) 1.81
Nano-imaging of the beating mouse heart in vivo: Importance of sarcomere dynamics, as opposed to sarcomere length per se, in the regulation of cardiac function. J Gen Physiol (2016) 1.49
Build it up-Tear it down: protein quality control in the cardiac sarcomere. Cardiovasc Res (2008) 1.42
Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res (2012) 1.39
Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. Cardiovasc Res (2009) 1.18
The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res (2009) 1.16
Cardiac myosin binding protein-C: redefining its structure and function. Biophys Rev (2012) 1.15
Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol (2012) 1.13
Roles for cardiac MyBP-C in maintaining myofilament lattice rigidity and prolonging myosin cross-bridge lifetime. Biophys J (2011) 1.11
Mechanical unfolding of cardiac myosin binding protein-C by atomic force microscopy. Biophys J (2011) 1.03
Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice. EMBO Mol Med (2013) 1.01
Differential contribution of cardiac sarcomeric proteins in the myofibrillar force response to stretch. Pflugers Arch (2008) 0.99
Scanning ion conductance microscopy: a convergent high-resolution technology for multi-parametric analysis of living cardiovascular cells. J R Soc Interface (2011) 0.98
Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression. J Biol Chem (2013) 0.96
Impaired contractile function due to decreased cardiac myosin binding protein C content in the sarcomere. Am J Physiol Heart Circ Physiol (2013) 0.96
How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2010) 0.96
Automated analysis of contractile force and Ca2+ transients in engineered heart tissue. Am J Physiol Heart Circ Physiol (2014) 0.92
Cardiac myosin binding protein-C is essential for thick-filament stability and flexural rigidity. Biophys J (2009) 0.92
Repair of Mybpc3 mRNA by 5'-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy. Mol Ther Nucleic Acids (2013) 0.92
Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol (2014) 0.92
Myocardial short-range force responses increase with age in F344 rats. J Mol Cell Cardiol (2008) 0.91
Functional dissection of myosin binding protein C phosphorylation. J Mol Cell Cardiol (2013) 0.91
Cardiac Myosin-binding protein C modulates the tuning of the molecular motor in the heart. Biophys J (2008) 0.90
Reversal of cardiac myocyte dysfunction as a unique mechanism of rescue by P2X4 receptors in cardiomyopathy. Am J Physiol Heart Circ Physiol (2009) 0.89
Herpesvirus-mediated delivery of a genetically encoded fluorescent Ca(2+) sensor to canine cardiomyocytes. J Biomed Biotechnol (2009) 0.89
Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function. Cell Rep (2015) 0.89
In vivo cardiac myosin binding protein C gene transfer rescues myofilament contractile dysfunction in cardiac myosin binding protein C null mice. Circ Heart Fail (2012) 0.88
Myosin cross-bridge dynamics in patients with hypertension and concentric left ventricular remodeling. Circ Heart Fail (2012) 0.86
Nicotinic acid adenine dinucleotide phosphate (NAADP)-mediated calcium signaling and arrhythmias in the heart evoked by β-adrenergic stimulation. J Biol Chem (2013) 0.86
Long term ablation of protein kinase A (PKA)-mediated cardiac troponin I phosphorylation leads to excitation-contraction uncoupling and diastolic dysfunction in a knock-in mouse model of hypertrophic cardiomyopathy. J Biol Chem (2014) 0.86
Ablation of cardiac myosin-binding protein-C accelerates contractile kinetics in engineered cardiac tissue. J Gen Physiol (2013) 0.85
Axial distribution of myosin binding protein-C is unaffected by mutations in human cardiac and skeletal muscle. J Muscle Res Cell Motil (2012) 0.85
Enhanced Ca²+ influx through cardiac L-type Ca²+ channels maintains the systolic Ca²+ transient in early cardiac atrophy induced by mechanical unloading. Pflugers Arch (2013) 0.84
FHL2 expression and variants in hypertrophic cardiomyopathy. Basic Res Cardiol (2014) 0.84
Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy. World J Diabetes (2015) 0.80
Cardiac myosin binding protein C and MAP-kinase activating death domain-containing gene polymorphisms and diastolic heart failure. PLoS One (2012) 0.79
ADP-stimulated contraction: A predictor of thin-filament activation in cardiac disease. Proc Natl Acad Sci U S A (2015) 0.78
Novel Phenotype-Genotype Correlations of Restrictive Cardiomyopathy With Myosin-Binding Protein C (MYBPC3) Gene Mutations Tested by Next-Generation Sequencing. J Am Heart Assoc (2015) 0.78
Impact of AT2 receptor deficiency on postnatal cardiovascular development. PLoS One (2012) 0.77
S-glutathiolation impairs phosphoregulation and function of cardiac myosin-binding protein C in human heart failure. FASEB J (2016) 0.76
Epigallocatechin-3-Gallate Accelerates Relaxation and Ca(2+) Transient Decay and Desensitizes Myofilaments in Healthy and Mybpc3-Targeted Knock-in Cardiomyopathic Mice. Front Physiol (2016) 0.75
Slowing of contractile kinetics by myosin-binding protein C can be explained by its cooperative binding to the thin filament. J Mol Cell Cardiol (2015) 0.75
Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy. Heart Fail Rev (2017) 0.75
Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation (2003) 5.85
Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med (2006) 4.74
What is the role of beta-adrenergic signaling in heart failure? Circ Res (2003) 3.22
Inhibition of elevated Ca2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ Res (2010) 2.38
Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation (2006) 2.26
Can phrenic stimulation protect the diaphragm from mechanical ventilation-induced damage? Eur Respir J (2013) 2.21
Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice. Cardiovasc Res (2005) 2.11
Diaphragm dysfunction on admission to the intensive care unit. Prevalence, risk factors, and prognostic impact-a prospective study. Am J Respir Crit Care Med (2013) 2.10
Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc Res (2005) 2.08
Reduced phospholamban phosphorylation is associated with impaired relaxation in left ventricular myocytes from neuronal NO synthase-deficient mice. Circ Res (2007) 2.07
Development of a drug screening platform based on engineered heart tissue. Circ Res (2010) 2.04
Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation (2009) 2.01
Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. Circulation (2006) 2.00
CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther (2004) 1.90
The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun (2012) 1.88
Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. J Mol Cell Cardiol (2007) 1.85
Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther (2002) 1.84
GFP expression in muscle cells impairs actin-myosin interactions: implications for cell therapy. Nat Methods (2006) 1.83
MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol (2010) 1.74
Role of oxidative stress in cardiac dysfunction of PPARalpha-/- mice. Am J Physiol Heart Circ Physiol (2007) 1.73
Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One (2011) 1.73
Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J Mol Cell Cardiol (2004) 1.72
Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes. J Am Coll Cardiol (2013) 1.68
Capturing adenylyl cyclases as potential drug targets. Nat Rev Drug Discov (2009) 1.66
Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation (2002) 1.65
Effect of MyBP-C binding to actin on contractility in heart muscle. J Gen Physiol (2003) 1.62
Myosin-binding protein C phosphorylation, myofibril structure, and contractile function during low-flow ischemia. Circulation (2005) 1.59
Ca(2+)-related signaling and protein phosphorylation abnormalities play central roles in a new experimental model of electrical storm. Circulation (2011) 1.58
Regulation of cardiac cAMP synthesis and contractility by nucleoside diphosphate kinase B/G protein beta gamma dimer complexes. Circ Res (2007) 1.58
Beta-adrenergic stimulation induces cardiac ankyrin repeat protein expression: involvement of protein kinase A and calmodulin-dependent kinase. Cardiovasc Res (2003) 1.56
Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation (2009) 1.54
The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys Acta (2008) 1.53
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol (2008) 1.53
Heme oxygenase-1 and its reaction product, carbon monoxide, prevent inflammation-related apoptotic liver damage in mice. Hepatology (2003) 1.52
Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J Hypertens (2002) 1.50
Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med (2010) 1.49
Engineering bioartificial tracheal tissue using hybrid fibroblast-mesenchymal stem cell cultures in collagen hydrogels. Interact Cardiovasc Thorac Surg (2010) 1.46
Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ Res (2013) 1.44
Cardiac grafting of engineered heart tissue in syngenic rats. Circulation (2002) 1.43
Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. Cardiovasc Res (2008) 1.42
Desmosomal gene analysis in arrhythmogenic right ventricular dysplasia/cardiomyopathy: spectrum of mutations and clinical impact in practice. Europace (2010) 1.40
Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev (2009) 1.40
Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. Cardiovasc Res (2004) 1.39
Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res (2004) 1.38
Engineered heart tissue for regeneration of diseased hearts. Biomaterials (2004) 1.36
Heart muscle engineering: an update on cardiac muscle replacement therapy. Cardiovasc Res (2006) 1.32
Cardiac tissue engineering: state of the art. Circ Res (2014) 1.30
Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J Clin Invest (2010) 1.29
Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. J Mol Cell Cardiol (2011) 1.27
Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. Circ Res (2009) 1.26
Expression of ten RGS proteins in human myocardium: functional characterization of an upregulation of RGS4 in heart failure. Cardiovasc Res (2002) 1.21
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail (2011) 1.20
Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function. Circ Heart Fail (2011) 1.20
Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. Cardiovasc Res (2009) 1.18
Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes. Biochem Biophys Res Commun (2006) 1.17
Cardiac ankyrin repeat protein, a negative regulator of cardiac gene expression, is augmented in human heart failure. Biochem Biophys Res Commun (2002) 1.17
The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res (2009) 1.16
Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy. Hum Mol Genet (2012) 1.16
How do MYBPC3 mutations cause hypertrophic cardiomyopathy? J Muscle Res Cell Motil (2011) 1.15
Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy. J Mol Biol (2008) 1.15
Green fluorescent protein impairs actin-myosin interactions by binding to the actin-binding site of myosin. J Biol Chem (2007) 1.14
The ubiquitin-proteasome system in cardiomyopathies. Curr Opin Cardiol (2011) 1.14
Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol (2012) 1.13
Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J (2003) 1.13
Thyroid hormone regulates developmental titin isoform transitions via the phosphatidylinositol-3-kinase/ AKT pathway. Circ Res (2007) 1.12
Terminal differentiation, advanced organotypic maturation, and modeling of hypertrophic growth in engineered heart tissue. Circ Res (2011) 1.12
Parthenogenetic stem cells for tissue-engineered heart repair. J Clin Invest (2013) 1.11
Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nat Cell Biol (2013) 1.11
Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy. Basic Res Cardiol (2011) 1.10